No Detail Found!

Efficacy and safety of dapagliflozin combined with insulin in overweight or obese individuals with type 2 diabetes

Author(s)
Xiaolong Li Endocrine Department, Harrison International Peace Hospital,Hengshui, Hebei Province,China
Dianjing Sun Endocrine Department, Harrison International Peace Hospital,Hengshui, Hebei Province,China
Yan Zhang Endocrine Department, Harrison International Peace Hospital,Hengshui, Hebei Province,China
Wei Gu Endocrine Department, Harrison International Peace Hospital,Hengshui, Hebei Province,China
Kunjie Zheng Endocrine Department, Harrison International Peace Hospital,Hengshui, Hebei Province,China
Abstract
To investigate the efficacy and safety of dapagliflozin plus insulin in overweight or obese individuals with type 2 diabetes, from January to June 2019, 85 patients with type 2 diabetes were treated at Harrison International Peace Hospital and were randomized to either a combination group (43 cases) or a control group (42 cases). The control group received insulin, whereas the combination group additionally received dapagliflozin. On the first, second, fifth and tenth days, insulin doses and the time taken for standardized blood glucose were documented and their effectiveness and safety were compared. The time taken for standard insulin in the combination group was shorter vs. control group [(4.32±0.41) d vs. (6.93±0.57) d] and the difference in the dosage of insulin statistically significant (all P<0.05); there were significant differences in fasting blood glucose (FPG), 2h postprandial blood glucose (2hPBG) and hemoglobin a1c (HbA1c), fasting serum insulin (FINS) and homeostatic model assessment of beta (HOMA-ß) between the two groups and within the two groups (all P<0.05); the incidence of adverse reactions was lower in the combination grou [4.65% (2/43) vs. 11.90% (6/42)] (P<0.05). Dapagliflozin plus insulin improves blood glucose and islet ß cell activity with a good safety profile in overweight or obese individuals with type 2 diabetes.
Publication Details
Page(s) 1349-1354
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: S4, Year: 2023

Request the full text from PASTIC

Keywords
type 2 diabetes, Safety, Overweight, efficacy, Insulin, Obese, Dapagliflozin
References
Bao P,Mi J,Yu Z,Liu L,Zhu Z,Liu S,Nan Z S .2021 .Efficacy and safety of acupuncture combined with Chinese herbal medicine in the treatment of type 2 diabetes mellitus: A protocol for a systematic review and meta-analysis. Medicine (Baltimore), 100(43) : e27658.
Chertow GM,Vart P,Jongs N,Toto RD,Gorriz JL,Hou FF,McMurray JJV,Correa-Rotter R,Rossing P,Sjostrom CD,Stefánsson BV,Langkilde AM,Wheeler DC,Heerspink HJL .2021 .Effects of dapagliflozin in stage 4 chronic kidney disease. J. Am. Soc. Nephrol., 32(9) : 2352-2361.
Cocchi C,Coppi F,Farinetti A,Mattioli AV .2021 .Cardiovascular disease prevention and therapy in women with Type 2 diabetes. , 17(3) : 487-496.
Campione JR,Ritchie ND,Fishbein HA,Mardon RE,Johnson MC,Pace W,Birch RJ,Seeholzer EL,Zhang X,Proia K,Siegel KR,McKeever Bullard K KR .2022 .Use and Impact of Type 2 Diabetes Prevention Interventions. Am. J. Prev. Med, 63(4) : 603-610.
Dugani SB,Mielke MM,Vella A .2021 .Burden and management of type 2 diabetes in rural United States. Diabetes Metab. Res. Rev., 37(5) : e3410.
Dou Z,Xia Y,Zhang J,Li Y,Zhang Y,Zhao L,Huang Z,Sun H,Wu L,Han D,Liu Y .2021 .Syndrome differentiation and treatment regularity in traditional Chinese medicine for type 2 diabetes: A text mining analysis. Front Endocrinol (Lausanne), 12(1) : 728032.
Guo Z and Priefer R .2021 .Current progress in pharmacogenomics of Type 2 diabetes: A systemic overview. Diabetes Metab. Syndr., 15(5) : 102239.
Jongs N,Greene T,Chertow GM,McMurray JJV,Langkilde AM,Correa-Rotter R,Rossing P,Sjostrom CD,Stefansson BV,Toto RD,Wheeler DC,Heerspink HJL .2021 .Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol., 9(11) : 755-766.
Karagiannis T,Tsapas A,Athanasiadou E,Avgerinos I,Liakos A,Matthews DR,Bekiari E .2021 .GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res. Clin. Pract, 174(12) : 108737.
Kurian J,Mohanthy S,Nanjumdaiah RM .2022 .Mechanism of action of yoga on prevention and management of type 2 diabetes mellitus: Narrative review. J. Bodyw. Mov. Ther., 29(3) : 134-139.
Leccisotti L,Cinti F,Sorice GP,D'Amario D,Lorusso M,Guzzardi MA,Mezza T,Gugliandolo S,Cocchi C,Capece U,Indovina L,Ferraro PM,Iozzo P,Crea F,Giordano A,Giaccari A .2022 .Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: The DAPAHEART Trial: A preliminary report. , 21(1) : 173.
Ma CX,Ma XN,Guan CH,Li YD,Mauricio D,Fu SB D .2022 .Cardiovascular disease in type 2 diabetes mellitus: Progress toward personalized management. Cardiovasc Diabetol, 21(1) : 74.
Rizzo MR,Di Meo I,Polito R,Auriemma MC,Gambardella A,di Mauro G,Capuano A,Paolisso G .2022 .Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacol. Res., 176(11) : 106062.
Siasos G .2020 .Diabetes and cardiovascular disease. Curr. Pharm. Des., 26(46) : 5909-5910.
Tinajero MG,Malik VS .2021 .An update on the epidemiology of type 2 diabetes: A global perspective. Endocrinol. Metab. Clin. North. Am., 50(3) : 337-355.
Tamborlane WV,Laffel LM,Shehadeh N,Isganaitis E,Van Name M,Ratnayake J,Karlsson C,Norjavaara E .2022 .Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: A prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol., 10(5) : 341-350.
Wiviott SD,Raz I,Bonaca MP,Mosenzon O,Kato ET,Cahn A,Silverman MG,Zelniker TA,Kuder JF,Murphy SA,Bhatt DL,Leiter LA,McGuire DK,Wilding JPH,Ruff CT,Gause-Nilsson IAM,Fredriksson M,Johansson PA,Langkilde AM,Sabatine MS .2019 .Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med, 380(4) : 347-357.
Zelniker TA,Wiviott SD,Raz I,Im K,Goodrich EL,Bonaca MP,Mosenzon O,Kato ET,Cahn A,Furtado RHM,Bhatt DL,Leiter LA,McGuire DK,Wilding JPH,Sabatine MS .2019 .SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet., 393(10166) : 31-39.
Zhao X,Liu L,Liu J .2022 .Treatment of type 2 diabetes mellitus using the traditional Chinese medicine Jinlida as an add-on medication: A systematic review and meta-analysis of randomized controlled trials. Front. Endocrinol. (Lausanne), 13(5) : 1018450.
Zhang Y,Hou J,Zeng Z J .2022 .Analysis of prescription medication rules of traditional Chinese medicine for diabetes treatment based on data mining. J. Healthc Eng, 7653765 : .
0

Citations

0

Downloads

85

Views